Open-Label, Randomised, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children from 10 to less than 18 years of age with relapsing-remitting multple sclerosis, with optional open-label extension